After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
December 05, 2013 09:15 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 5, 2013) - Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced,...
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
November 05, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have...
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
August 28, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
August 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Stock Market Media Group Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report
August 15, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 15, 2013) - Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its...
Nuvilex, Inc. Strengthens Its Hand in the Cancer Arena With Purchase of Assets
July 30, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 30, 2013) - Nuvilex, Inc. (OTCQB: NVLX) became a much more valuable company in July when it closed a deal it was fully prepared to pay a great deal more money for,...
Nuvilex, Inc. Moves Closer to Head to Head With Eli Lilly in Phase III Clinical Trials
July 25, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly's blockbuster cancer drug, Gemzar, and doing so with the knowledge...
Nuvilex, Inc. a Biotech Developing Treatments for Healthcare's Hard Targets
June 26, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) executives aren't daunted by the statistics. As a matter of fact, they're aware the research they do is directed...
Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With Successful Phase III Trials
May 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 22, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is a diamond in the rough in the truest sense. Currently shares of the Silver Spring, Maryland, biotechnology firm can...
Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar
May 20, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2013) - The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner's treatment. Two biotechnology...